{"id":323658,"date":"2026-10-22T12:34:04","date_gmt":"2026-10-22T07:04:04","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=323658"},"modified":"2026-10-22T12:34:04","modified_gmt":"2026-10-22T07:04:04","slug":"domestic-brand-pharma-global-generics-leader-and-injectables-stocks-roadmap-outpost-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/domestic-brand-pharma-global-generics-leader-and-injectables-stocks-roadmap-outpost-list\/","title":{"rendered":"3 Domestic Brand Pharma, Global Generics Leader and Injectables Stocks With a Strong Future Roadmap: JB Chemicals and Pharmaceuticals, Lupin and Aurobindo Pharma"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>JB Chemicals and Pharmaceuticals, Lupin and Aurobindo Pharma: ROE of 9.2% to 23.8% and FY22 to FY26 revenue CAGR of 9.5% to 15.0%. Prices as of 21 Oct 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three large pharma and domestic brand stocks to watch are JB Chemicals and Pharmaceuticals, Lupin and Aurobindo Pharma. Their return on equity ranges from 9.2% to 23.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.5% to 15.0%. Lupin leads on both return on equity at 23.8% and revenue growth at 15.0% a year. Prices are based on the 21 October 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Large pharma and domestic brand stocks let investors follow companies that combine strong prescription brands with global generics. JB Chemicals and Pharmaceuticals, Lupin and Aurobindo Pharma cover domestic brands, a global generics and specialty franchise and a large generics and injectables portfolio.<\/p>\n<p>This list covers three large pharma and domestic brand stocks with complete current figures: JB Chemicals and Pharmaceuticals, Lupin and Aurobindo Pharma. Every figure comes from the latest reported financials and the 21 October 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=domestic-brand-pharma-global-generics-leader-and-injectables-stocks-roadmap-outpost-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/domestic-brand-pharma-global-generics-leader-and-injectables-stocks-roadmap-outpost-list\/#What_Are_Large_Pharma_and_Domestic_Brand_Stocks\" title=\"What Are Large Pharma and Domestic Brand Stocks?\">What Are Large Pharma and Domestic Brand Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/domestic-brand-pharma-global-generics-leader-and-injectables-stocks-roadmap-outpost-list\/#Large_Pharma_and_Domestic_Brand_Stocks_at_a_Glance\" title=\"Large Pharma and Domestic Brand Stocks at a Glance\">Large Pharma and Domestic Brand Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/domestic-brand-pharma-global-generics-leader-and-injectables-stocks-roadmap-outpost-list\/#Why_Do_Large_Pharma_and_Domestic_Brand_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Large Pharma and Domestic Brand Stocks Have a Strong Roadmap in India?\">Why Do Large Pharma and Domestic Brand Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/domestic-brand-pharma-global-generics-leader-and-injectables-stocks-roadmap-outpost-list\/#Why_JB_Chemicals_and_Pharmaceuticals_Features_Among_These_Large_Pharma_and_Domestic_Brand_Stocks\" title=\"Why JB Chemicals and Pharmaceuticals Features Among These Large Pharma and Domestic Brand Stocks\">Why JB Chemicals and Pharmaceuticals Features Among These Large Pharma and Domestic Brand Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/domestic-brand-pharma-global-generics-leader-and-injectables-stocks-roadmap-outpost-list\/#Why_Lupin_Features_Among_These_Large_Pharma_and_Domestic_Brand_Stocks\" title=\"Why Lupin Features Among These Large Pharma and Domestic Brand Stocks\">Why Lupin Features Among These Large Pharma and Domestic Brand Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/domestic-brand-pharma-global-generics-leader-and-injectables-stocks-roadmap-outpost-list\/#Why_Aurobindo_Pharma_Features_Among_These_Large_Pharma_and_Domestic_Brand_Stocks\" title=\"Why Aurobindo Pharma Features Among These Large Pharma and Domestic Brand Stocks\">Why Aurobindo Pharma Features Among These Large Pharma and Domestic Brand Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/domestic-brand-pharma-global-generics-leader-and-injectables-stocks-roadmap-outpost-list\/#JB_Chemicals_and_Pharmaceuticals_vs_Lupin_vs_Aurobindo_Pharma_on_Key_Financials\" title=\"JB Chemicals and Pharmaceuticals vs Lupin vs Aurobindo Pharma on Key Financials\">JB Chemicals and Pharmaceuticals vs Lupin vs Aurobindo Pharma on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/domestic-brand-pharma-global-generics-leader-and-injectables-stocks-roadmap-outpost-list\/#Key_Risks_to_Check_Before_Investing_in_Large_Pharma_and_Domestic_Brand_Stocks\" title=\"Key Risks to Check Before Investing in Large Pharma and Domestic Brand Stocks\">Key Risks to Check Before Investing in Large Pharma and Domestic Brand Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/domestic-brand-pharma-global-generics-leader-and-injectables-stocks-roadmap-outpost-list\/#Final_Thoughts_on_Large_Pharma_and_Domestic_Brand_Stocks\" title=\"Final Thoughts on Large Pharma and Domestic Brand Stocks\">Final Thoughts on Large Pharma and Domestic Brand Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/domestic-brand-pharma-global-generics-leader-and-injectables-stocks-roadmap-outpost-list\/#What_are_large_pharma_and_domestic_brand_stocks\" title=\"What are large pharma and domestic brand stocks?\">What are large pharma and domestic brand stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/domestic-brand-pharma-global-generics-leader-and-injectables-stocks-roadmap-outpost-list\/#Which_large_pharma_and_domestic_brand_stocks_are_covered_in_this_list\" title=\"Which large pharma and domestic brand stocks are covered in this list?\">Which large pharma and domestic brand stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/domestic-brand-pharma-global-generics-leader-and-injectables-stocks-roadmap-outpost-list\/#Why_do_large_pharma_and_domestic_brand_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do large pharma and domestic brand stocks have a strong future roadmap in India?\">Why do large pharma and domestic brand stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/domestic-brand-pharma-global-generics-leader-and-injectables-stocks-roadmap-outpost-list\/#How_has_JB_Chemicals_and_Pharmaceuticals_performed_financially\" title=\"How has JB Chemicals and Pharmaceuticals performed financially?\">How has JB Chemicals and Pharmaceuticals performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/domestic-brand-pharma-global-generics-leader-and-injectables-stocks-roadmap-outpost-list\/#How_has_Lupin_performed_financially\" title=\"How has Lupin performed financially?\">How has Lupin performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/domestic-brand-pharma-global-generics-leader-and-injectables-stocks-roadmap-outpost-list\/#How_has_Aurobindo_Pharma_performed_financially\" title=\"How has Aurobindo Pharma performed financially?\">How has Aurobindo Pharma performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/domestic-brand-pharma-global-generics-leader-and-injectables-stocks-roadmap-outpost-list\/#What_risks_should_investors_check_before_buying_large_pharma_and_domestic_brand_stocks\" title=\"What risks should investors check before buying large pharma and domestic brand stocks?\">What risks should investors check before buying large pharma and domestic brand stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/domestic-brand-pharma-global-generics-leader-and-injectables-stocks-roadmap-outpost-list\/#Is_this_list_of_large_pharma_and_domestic_brand_stocks_investment_advice\" title=\"Is this list of large pharma and domestic brand stocks investment advice?\">Is this list of large pharma and domestic brand stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Large_Pharma_and_Domestic_Brand_Stocks\"><\/span><strong>What Are Large Pharma and Domestic Brand Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Large pharma and domestic brand stocks are listed pharmaceutical companies that sell prescription brands in India and generics and specialty products in regulated markets. Their earnings depend on prescription growth, product approvals and plant capacity.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Large_Pharma_and_Domestic_Brand_Stocks_at_a_Glance\"><\/span><strong>Large Pharma and Domestic Brand Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/jbchepharm\/jb-chemicals-and-pharmaceuticals-ltd-share-price-today\">JB Chemicals and Pharmaceuticals<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,408.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">38,731<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">54.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.00<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/lupin\/lupin-ltd-share-price-today\">Lupin<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,964<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">89,343<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">23.8<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.29<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/auropharma\/aurobindo-pharma-ltd-share-price-today\">Aurobindo Pharma<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,578.8<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">92,924<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">25.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9.2<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.21<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, Lupin and Aurobindo Pharma trade at a P\/E below the industry P\/E, while JB Chemicals and Pharmaceuticals trades above it, which reflects the growth the market already expects. Readers comparing large pharma and domestic brand stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Large_Pharma_and_Domestic_Brand_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Large Pharma and Domestic Brand Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Large pharma and domestic brand stocks have a strong roadmap in India because rising demand for chronic care at home and steady sourcing of quality generics abroad support growth in both markets.<\/p>\n<ul>\n<li><strong>Domestic prescriptions.<\/strong> Strong brands keep winning share with doctors.<\/li>\n<li><strong>Global generics.<\/strong> Regulated markets keep sourcing quality medicines from India.<\/li>\n<li><strong>Wider range.<\/strong> Injectables and specialty products add higher-value sales.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_JB_Chemicals_and_Pharmaceuticals_Features_Among_These_Large_Pharma_and_Domestic_Brand_Stocks\"><\/span><strong>Why JB Chemicals and Pharmaceuticals Features Among These Large Pharma and Domestic Brand Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the large pharma and domestic brand stocks on this list, JB Chemicals and Pharmaceuticals is a Mumbai-based pharmaceutical company that sells branded formulations in India in cardiac, gastro-intestinal and other therapies, exports to several markets and runs a contract development and manufacturing business.<\/p>\n<p>Revenue rose from Rs 2,463 crore in FY22 to Rs 4,208 crore in FY26, a compound annual growth rate of 14.3%. Net profit grew from Rs 386 crore in FY22 to Rs 709 crore in FY26, which works out to a compound annual growth rate of 16.4%.<\/p>\n<p>The company has a return on equity of 17.1%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 38,731 crore. The stock trades at a P\/E of 54.6, above the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> The company is strengthening its domestic brands through field force expansion and acquisitions while building its contract manufacturing arm for global customers. A mix of chronic and acute brands supports steady prescription demand.<\/p>\n<p><strong>What to watch:<\/strong> Monitor the growth of key domestic brands and the order flow in contract manufacturing.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Lupin_Features_Among_These_Large_Pharma_and_Domestic_Brand_Stocks\"><\/span><strong>Why Lupin Features Among These Large Pharma and Domestic Brand Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the global generic shares on this list, Lupin is a Mumbai-headquartered global pharmaceutical company with a presence in branded generics in India, complex generics and specialty products in the United States, and active ingredients, with strength in respiratory, cardiovascular, anti-diabetic and anti-infective therapies.<\/p>\n<p>In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore. Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%.<\/p>\n<p>Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%. The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P\/E of 16.1, below the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> The company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.<\/p>\n<p><strong>What to watch:<\/strong> Track key launches in the United States, especially in inhalation and complex injectables, and the growth of the India branded business.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Aurobindo_Pharma_Features_Among_These_Large_Pharma_and_Domestic_Brand_Stocks\"><\/span><strong>Why Aurobindo Pharma Features Among These Large Pharma and Domestic Brand Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Aurobindo Pharma is a Hyderabad-based pharmaceutical company that makes generic formulations, active ingredients and injectables, with the United States and Europe as its largest markets.<\/p>\n<p>The company has a return on equity of 9.2%, a debt to equity ratio of 0.21 and a market capitalisation of Rs 92,924 crore. The stock trades at a P\/E of 25.0, below the industry P\/E of 36.0.<\/p>\n<p>Revenue rose from Rs 23,776 crore in FY22 to Rs 34,145 crore in FY26, a compound annual growth rate of 9.5%. Net profit grew from Rs 2,647 crore in FY22 to Rs 3,503 crore in FY26, which works out to a compound annual growth rate of 7.3%. In the June 2026 quarter, revenue grew 18.1% year on year to Rs 9,415 crore, while net profit rose 25.2% to Rs 1,032 crore.<\/p>\n<p><strong>Roadmap:<\/strong> The company is widening its range into injectables, biosimilars and complex generics while keeping a large base in oral solid dosages. Its integrated manufacturing from ingredients to finished products supports supply to regulated markets.<\/p>\n<p><strong>What to watch:<\/strong> Monitor new product launches and progress on its biosimilars and injectables pipeline.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"JB_Chemicals_and_Pharmaceuticals_vs_Lupin_vs_Aurobindo_Pharma_on_Key_Financials\"><\/span><strong>JB Chemicals and Pharmaceuticals vs Lupin vs Aurobindo Pharma on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three large pharma and domestic brand stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">JB Chemicals and Pharmaceuticals<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,463<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4,208<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">14.3%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">709<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16.9%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Lupin<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16,616<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">29,039<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.0%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,355<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">18.4%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Aurobindo Pharma<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">23,776<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">34,145<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9.5%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,503<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">10.3%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Lupin posts the highest return on equity in this group at 23.8%. Aurobindo Pharma has the largest FY26 revenue at Rs 34,145 crore, and Lupin shows the fastest revenue growth with a 15.0% compound annual rate. A useful habit with large pharma and domestic brand stocks is to check each new quarterly result against the capacity plans the company described earlier.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Large_Pharma_and_Domestic_Brand_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Large Pharma and Domestic Brand Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these large pharma and domestic brand stocks, the main points are: Long-term global generic shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Pricing pressure.<\/strong> Competition can lower the prices of widely available generics.<\/li>\n<li><strong>Regulatory inspections.<\/strong> Plants must keep meeting the standards of global regulators.<\/li>\n<li><strong>Valuation levels.<\/strong> Some of these companies trade at high earnings multiples, so growth must continue to justify them.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter large pharma and domestic brand stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Large_Pharma_and_Domestic_Brand_Stocks\"><\/span><strong>Final Thoughts on Large Pharma and Domestic Brand Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Large pharma and domestic brand stocks reward investors who follow prescription trends, approvals and plant utilisation together. JB Chemicals and Pharmaceuticals, Lupin and Aurobindo Pharma each pair brand strength with scale. Based on the 21 October 2026 close, JB Chemicals and Pharmaceuticals trades at Rs 2,408.9, Lupin at Rs 1,964 and Aurobindo Pharma at Rs 1,578.8. Valuation matters as much as growth, so compare each company&#8217;s P\/E with its industry P\/E before adding any of these large pharma and domestic brand stocks to a watchlist.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track large pharma and domestic brand stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_large_pharma_and_domestic_brand_stocks\"><\/span><strong>What are large pharma and domestic brand stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Large pharma and domestic brand stocks are listed pharmaceutical companies that sell prescription brands in India and generics and specialty products in regulated markets. Their earnings depend on prescription growth, product approvals and plant capacity. This list looks at three of them, JB Chemicals and Pharmaceuticals, Lupin and Aurobindo Pharma, using reported FY22 to FY26 financials and the 21 October 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_large_pharma_and_domestic_brand_stocks_are_covered_in_this_list\"><\/span><strong>Which large pharma and domestic brand stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers JB Chemicals and Pharmaceuticals, Lupin and Aurobindo Pharma. Based on the 21 October 2026 close, JB Chemicals and Pharmaceuticals traded at Rs 2,408.9, Lupin at Rs 1,964 and Aurobindo Pharma at Rs 1,578.8. Their return on equity ranges from 9.2% to 23.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.5% to 15.0%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_large_pharma_and_domestic_brand_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do large pharma and domestic brand stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Large pharma and domestic brand stocks have a strong roadmap in India because rising demand for chronic care at home and steady sourcing of quality generics abroad support growth in both markets. The main drivers are as follows. Domestic prescriptions. Strong brands keep winning share with doctors. Global generics. Regulated markets keep sourcing quality medicines from India. Wider range. Injectables and specialty products add higher-value sales. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_JB_Chemicals_and_Pharmaceuticals_performed_financially\"><\/span><strong>How has JB Chemicals and Pharmaceuticals performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 2,463 crore in FY22 to Rs 4,208 crore in FY26, a compound annual growth rate of 14.3%. Net profit grew from Rs 386 crore in FY22 to Rs 709 crore in FY26, which works out to a compound annual growth rate of 16.4%. The company has a return on equity of 17.1%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 38,731 crore. The stock trades at a P\/E of 54.6, above the industry P\/E of 36.0. Looking ahead, the company is strengthening its domestic brands through field force expansion and acquisitions while building its contract manufacturing arm for global customers. A mix of chronic and acute brands supports steady prescription demand.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Lupin_performed_financially\"><\/span><strong>How has Lupin performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%. In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore. The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P\/E of 16.1, below the industry P\/E of 36.0. Looking ahead, the company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Aurobindo_Pharma_performed_financially\"><\/span><strong>How has Aurobindo Pharma performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 23,776 crore in FY22 to Rs 34,145 crore in FY26, a compound annual growth rate of 9.5%. Net profit grew from Rs 2,647 crore in FY22 to Rs 3,503 crore in FY26, which works out to a compound annual growth rate of 7.3%. In the June 2026 quarter, revenue grew 18.1% year on year to Rs 9,415 crore, while net profit rose 25.2% to Rs 1,032 crore. The company has a return on equity of 9.2%, a debt to equity ratio of 0.21 and a market capitalisation of Rs 92,924 crore. The stock trades at a P\/E of 25.0, below the industry P\/E of 36.0. Looking ahead, the company is widening its range into injectables, biosimilars and complex generics while keeping a large base in oral solid dosages. Its integrated manufacturing from ingredients to finished products supports supply to regulated markets.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_large_pharma_and_domestic_brand_stocks\"><\/span><strong>What risks should investors check before buying large pharma and domestic brand stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying large pharma and domestic brand stocks. Pricing pressure. Competition can lower the prices of widely available generics. Regulatory inspections. Plants must keep meeting the standards of global regulators. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_large_pharma_and_domestic_brand_stocks_investment_advice\"><\/span><strong>Is this list of large pharma and domestic brand stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 21 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are large pharma and domestic brand stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Large pharma and domestic brand stocks are listed pharmaceutical companies that sell prescription brands in India and generics and specialty products in regulated markets. Their earnings depend on prescription growth, product approvals and plant capacity. This list looks at three of them, JB Chemicals and Pharmaceuticals, Lupin and Aurobindo Pharma, using reported FY22 to FY26 financials and the 21 October 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which large pharma and domestic brand stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers JB Chemicals and Pharmaceuticals, Lupin and Aurobindo Pharma. Based on the 21 October 2026 close, JB Chemicals and Pharmaceuticals traded at Rs 2,408.9, Lupin at Rs 1,964 and Aurobindo Pharma at Rs 1,578.8. Their return on equity ranges from 9.2% to 23.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.5% to 15.0%.\"}},{\"@type\":\"Question\",\"name\":\"Why do large pharma and domestic brand stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Large pharma and domestic brand stocks have a strong roadmap in India because rising demand for chronic care at home and steady sourcing of quality generics abroad support growth in both markets. The main drivers are as follows. Domestic prescriptions. Strong brands keep winning share with doctors. Global generics. Regulated markets keep sourcing quality medicines from India. Wider range. Injectables and specialty products add higher-value sales. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has JB Chemicals and Pharmaceuticals performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 2,463 crore in FY22 to Rs 4,208 crore in FY26, a compound annual growth rate of 14.3%. Net profit grew from Rs 386 crore in FY22 to Rs 709 crore in FY26, which works out to a compound annual growth rate of 16.4%. The company has a return on equity of 17.1%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 38,731 crore. The stock trades at a P\/E of 54.6, above the industry P\/E of 36.0. Looking ahead, the company is strengthening its domestic brands through field force expansion and acquisitions while building its contract manufacturing arm for global customers. A mix of chronic and acute brands supports steady prescription demand.\"}},{\"@type\":\"Question\",\"name\":\"How has Lupin performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%. In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore. The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P\/E of 16.1, below the industry P\/E of 36.0. Looking ahead, the company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.\"}},{\"@type\":\"Question\",\"name\":\"How has Aurobindo Pharma performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 23,776 crore in FY22 to Rs 34,145 crore in FY26, a compound annual growth rate of 9.5%. Net profit grew from Rs 2,647 crore in FY22 to Rs 3,503 crore in FY26, which works out to a compound annual growth rate of 7.3%. In the June 2026 quarter, revenue grew 18.1% year on year to Rs 9,415 crore, while net profit rose 25.2% to Rs 1,032 crore. The company has a return on equity of 9.2%, a debt to equity ratio of 0.21 and a market capitalisation of Rs 92,924 crore. The stock trades at a P\/E of 25.0, below the industry P\/E of 36.0. Looking ahead, the company is widening its range into injectables, biosimilars and complex generics while keeping a large base in oral solid dosages. Its integrated manufacturing from ingredients to finished products supports supply to regulated markets.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying large pharma and domestic brand stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying large pharma and domestic brand stocks. Pricing pressure. Competition can lower the prices of widely available generics. Regulatory inspections. Plants must keep meeting the standards of global regulators. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of large pharma and domestic brand stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 21 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Large Pharma and Domestic Brand Stocks with a strong future roadmap: JB Chemicals and Pharmaceuticals, Lupin and Aurobindo Pharma. Compare price, valuation, return on equity and revenue growth as of 21 October 2026.<\/p>\n","protected":false},"author":34,"featured_media":323657,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[10618,3803,14732,14731,14176,14730,13958],"class_list":["post-323658","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-aurobindo-pharma","tag-best-stocks","tag-cardiac-brand-pharma-stocks","tag-global-generic-shares","tag-jb-chemicals-and-pharmaceuticals","tag-large-pharma-and-domestic-brand-stocks","tag-lupin"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["323657"],"rank_math_title":["Large Pharma and Domestic Brand Stocks to Watch"],"rank_math_description":["Compare 3 large pharma and domestic brand stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 21 Oct 2026."],"rank_math_focus_keyword":["large pharma and domestic brand stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/3-domestic-brand-pharma-global-generics-leader-and-injectables-stocks-with-a.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/323658","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=323658"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/323658\/revisions"}],"predecessor-version":[{"id":323659,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/323658\/revisions\/323659"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/323657"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=323658"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=323658"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=323658"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}